A new international guideline recommends Ekterly (sebetralstat), Kalvista Pharmaceuticals’ approved oral therapy for hereditary angioedema (HAE), as a first-line option for timely, on-demand resolution of HAE swelling attacks in children ages 12 and older. The committee behind these new pediatric guidelines stated in a study recommendation that adolescents with…